SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Feet of a person with red-painted toenails as the person steps onto a weight scale.
Cardiovascular disease
Rivus Targets Weight-Loss Drug Market With Mid-Stage Win in Obesity-Related Heart Failure
Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.
August 14, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of backpack and briefcase
Career Advice
Career Coach: How to Craft an Industry Resume After a Career in Academia
Plus, learn how to handle vacation time in a new job and navigate the stress of a recent promotion to leadership.
August 14, 2024
 · 
7 min read
 · 
Carina Clingman
Podcast
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
Lykos Therapeutics will ask the FDA to reconsider its rejection of the company’s MDMA-assisted PTSD therapy, Pfizer scores positive Phase III results for its RSV vaccine, a roundup of Q2 earnings season and more.
August 14, 2024
 · 
1 min read
 · 
Heather McKenzie
Lonely drunk woman sitting on bar counter feels depressed spends time with strong alcoholic beverages holds glass drinking booze having dependence, addiction. Concept of alcoholism and social problems
psychedelics
Atai Touts Early Data on Psychedelic Depression Drug, Plans Phase II Trial
On the heels of last week’s FDA rejection of Lykos’ MDMA-assisted PTSD therapy, Atai announced Tuesday positive preliminary results for its DMT-based treatment for depression from a Phase Ib study.
August 13, 2024
 · 
2 min read
 · 
Nick Paul Taylor
BioNTech, BMS, Merck/Taylor Tieden for BioSpace
Earnings
Q2 Recap: Smooth Sailing for Some, but COVID Cliff and Vaccine Issues Thwart Others
While some biopharma companies beat expectations, others fell short for various reasons, with some deciding to return or axe assets.
August 13, 2024
 · 
6 min read
 · 
Tyler Patchen
Illustration of young woman standing in front of exit door
Layoffs
Boundless Bio Announces ‘Modest Reduction’ to San Diego Workforce
The layoffs are intended to help provide an operating runway into the fourth quarter of 2026.
August 13, 2024
 · 
1 min read
 · 
Angela Gabriel
Skin lesions of prurigo nodularis, including
Immunology and inflammation
Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis
The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
August 13, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of Novartis' office in Canada
Legal
Novartis Loses Court Case to Block Entresto Generics After FDA Denies Petition
On the heels of the FDA’s denial of its petition, a Delaware district court on Monday handed Novartis another loss in its efforts to keep the market free of Entresto copycats.
August 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk's logo on the facade of its building in Germany
Diabetes
Novo Refuses to Give Up on Insulin Icodec, Eyes Combo Filing With Semaglutide
By the end of the year, Novo Nordisk intends to make a regulatory filing for the combination of its icodec and semaglutide, keeping its once-weekly insulin program afloat.
August 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS